MedTrace Logo

Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)

NCT02582658 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 173

Last updated 2019-06-05

Study results available
· View outcomes & findings →

Summary

The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) +/- Ribavirin (RBV) in chronic hepatitis C virus (HCV) infected participants in Austria.

Conditions

  • Chronic Hepatitis C

Sponsors & Collaborators

Principal Investigators

  • Alexander P Dorr, PhD · AbbVie Austria

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-06
Primary Completion
2017-01-12
Completion
2017-01-12

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02582658 on ClinicalTrials.gov